Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-01-07 Linezolid
| Linezolid |
|
Formulary
|
Tablets 600mg On advice of Microbiology only. Severe optic neuropathy may occur rarely, particularly if linezolid is used for longer than 28 days. Haematopoietic disorders (including thrombocytopenia, anaemia, leucopenia, and pancytopenia) have been reported in patients receiving linezolid. It is recommended that full blood counts are monitored weekly. |
 LSCMMG: Linezolid LSCMMG: Linezolid Prescriber Information Sheet |
|
Links
- Blackpool Teaching Hospitals: Antimicrobial Formulary
- British Association for Sexual Health and HIV
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Lancashire and South Cumbria Critical Care - Vancomycin Guideline
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- LSCMMG prescribing information sheet: Colistimethate For Nebulisation in Adult Patients with Non-Cystic Fibrosis Bronchiectasis
- LSCMMG: Colistimethate for nebulisation (Colomycin®) - Prescribing Information Sheet
- LSCMMG: Fidaxomicin
- LSCMMG: Linezolid
- LSCMMG: Linezolid Prescriber Information Sheet
- LSCMMG: Oritavancin
- LSCMMG: Rifaximin
- MHRA Drug safety update Sept 2011: Systemic fusidic acid and interaction with statins
- MHRA: Colobreathe: risk of capsule breakage—new instructions for use
- MHRA: Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions
- MHRA: Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions
- MHRA: Systemic fusidic acid and interaction with statins
- MHRA: Systemic fusidic acid and interaction with statins
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE ESUOM25: Non-cystic fibrosis bronchiectasis: colistimethate sodium
- NICE evidence summary: Rifaximin for pouchitis
- NICE NG110: Prostatitis (acute): antimicrobial prescribing
- NICE NG111: Pyelonephritis (acute): antimicrobial prescribing
- NICE NG114: Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
- NICE NG117: Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing
- NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing
- NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing
- NICE NG152: Leg ulcer infection: antimicrobial prescribing
- NICE NG153: Impetigo: antimicrobial prescribing
- NICE NG182: Insect bites and stings: antimicrobial prescribing
- NICE NG184: Human and animal bites: antimicrobial prescribing
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG190: Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG198: Acne vulgaris: management
- NICE NG199: Clostridioides difficile infection: antimicrobial prescribing
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG50: Cirrhosis in over 16s: assessment and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE NG79: Sinusitis (acute): antimicrobial prescribing
- NICE NG84: Sore throat (acute): antimicrobial prescribing
- NICE NG91: Otitis media (acute): antimicrobial prescribing
- NICE NG95: Lyme disease
- NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
- NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
- NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
- NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
- PHE: management and treatment of Clostridium difficile infection May 2013
- UHMB IV Vancomycin administration and monitoring guidelines
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023